Only it was still there when you went back to the dentist six months later. This time, there was a biopsy. It was cancer, the ...
Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...
JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...
A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...